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Abstract Our understanding of estrogen signaling has under-
gone a true paradigm shift over recent years, following the dis-
covery in 1995 of a second estrogen receptor, estrogen receptor
L (ERL). In many contexts ERL appears to antagonize the
actions of ERK (yin/yang relationship) although there also exist
genes that are speci¢cally regulated by one of the two receptors.
Studies of ERL knockout mice have shown that ERL exerts
important functions in the ovary, central nervous system, mam-
mary gland, prostate gland, hematopoiesis, immune system, ves-
sels and bone. The use of ERL-speci¢c ligands against certain
forms of cancer represents one of the many pharmaceutical
possibilities that have been created thanks to the discovery of
ERL.
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1. Estrogen receptor L, a new member of the steroid hormone
receptor family
Estrogen receptors (ER) belong to the steroid/retinoid re-
ceptor gene superfamily, the members of which share some
structural and functional similarities [1]. There are four struc-
turally distinct, functional domains in these proteins. From
the N-terminus to the C-terminus of the receptor molecule
these are: the N-terminal A/B region that contributes to tran-
scriptional activation function and harbors the activation
function 1 (AF-1); the mid-region also called the C region,
or the DBD, since it harbors the DNA binding domain (Fig.
1A). This is the region that mediates speci¢c DNA binding.
Next to the DBD is the D domain or the hinge region, a less
well-characterized region; at the C-terminus is the ligand
binding domain (LBD or E/F domain). LBD harbors the li-
gand binding pocket as well as sites for cofactor binding,
transactivation (AF-2), nuclear localization and interactions
with heat shock proteins. Functionally, upon ligand binding,
these receptors form dimers and modulate transcription by
binding to their corresponding hormone response element
(ERE for estrogen response element) in the promoter region
of target genes.
The ¢rst estrogen receptor, now named ERK, was cloned in
1986 [2,3], more than 20 years after it was identi¢ed by its
a⁄nity for 17L-estradiol. In 1996, the second ER, ERL, was
reported [4]. A schematic comparison of ERL and ERK is
shown in Fig. 1. There is 96% amino acid identity between
the two receptors in the DBD but in the LBD the homology is
only 53%. This suggests that ERL would recognize and bind
to similar EREs as ERK but that each receptor would have a
distinct spectrum of ligands. There is less conservation be-
tween the two receptors in the N-terminal AF-1 and C-termi-
nal AF-2. This suggests that di¡erent sets of proteins in the
transcription complexes may interact with ERK and ERL and
direct them to speci¢c targets. Such a mechanism could ex-
plain why at AP-1 sites, ERL and ERK function oppositely
[5]. Experimental evidence has shown that both ERs do bind
to classical EREs with similar a⁄nities and that their a⁄nities
for 17L-estradiol (E2) are quite similar (0.6 nM for ERL and
0.2 nM for ERK) [4,6]. However, many other ligands show
preferential binding to one or the other ER. Some natural
dietary components, coumestrol and genistein, show a prefer-
ence for binding ERL [7] and can probably be further modi-
¢ed to create K- and L-selective estrogen receptor modulators.
The chemical structures of three ER ligands are shown in
Fig. 2.
E2 target tissues can be divided into two groups, the clas-
sical and non-classical E2 target tissues, respectively. The clas-
sical targets are the uterus, mammary gland, placenta, liver,
central nervous system (CNS), cardiovascular system, bone.
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These tissues have a high ERK content and respond to E2
challenge with increases in transcription of certain E2-respon-
sive genes. The non-classical target tissues include prostate,
testis, ovary, pineal gland, thyroid gland, parathyroids, adre-
nals, pancreas, gallbladder, skin, urinary tract, lymphoid and
erythroid tissues. In these tissues, expression of ERK is either
very low or not measurable. ERL is highly expressed in non-
classical E2 target tissues like the prostate epithelium, urogen-
ital tract, ovarian follicles, lung, intestinal epithelium, certain
ERK-de¢cient brain regions and muscle [8].
In mature females the major estrogen target tissue is the
uterus. It contains very little ERL but is abundant in ERK.
It was from this tissue that Jensen and Jacobsen found speci¢c
binding of E2, and concluded that the biological e¡ects of
estrogen had to be mediated by a receptor protein [9]. In
the breast, E2 stimulates growth and the estrogen receptor
antagonist tamoxifen has been the most e¡ective treatment
for ERK-positive breast cancer [10]. The reason that ERL
was not found until 1995 is probably because the focus of
estrogen studies had not been directed to tissues where ERL
is abundant. Although some studies explored estrogen actions
in tissues like the ventral prostate, where ERK expression is
low, interpretation of the data was always colored by the view
that ERK was the only ER. It is possible that if the prostate,
lung or granulosa cells had been used to clone ER, ERL
would have been the ¢rst ER to be found.
It is generally accepted that ER sediments at 8S when cy-
tosol is extracted with low salt bu¡er (10 mM KCl) and at 4S
when high salt bu¡er (100 mM KCl) is used [11]. When ERL
was cloned and expressed in insect cells, it was found that this
new ER sediments at 4S regardless of the salt concentrations
in the bu¡er [12^14]. Before 1995, there are some reports in
the literature where 4S E2 binding peaks were found when
tissues were analyzed [15^19]. These results were not under-
stood but today we know that these are ERL-containing tis-
sues, and the 4S peak was probably ERL. The reason for
di¡erent sedimentation properties between ERK and ERL
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Fig. 1. Structural comparison of ERK, ERL and ERL splice variants. The percent homology in the various functional domains of the two re-
ceptors is given in A. In B the structural organization of the ERL gene is illustrated. Exons 1^8 are utilized in ERL1 but, as illustrated in C, in
the splice variant ERLcx, exon 8 is replaced by the alternative exon, labeled cx.
Fig. 2. Chemical structure of the three estrogen receptor ligands dis-
cussed in this review. Top: 17L-estradiol, E2; bottom left: genistein;
and bottom right: 3LAdiol. The concentrations of each ligand
which will displace 50% of bound E2 from ERK and ERL are listed
as Ki.
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has not been carefully investigated but indications are that
ERL does not interact with those chaperones that normally
interact with ERK in low salt bu¡er.
In addition to the di¡erences in ligand binding and tissue
distribution referred to above, ERK and ERL also di¡er in
their cofactor interactions and their transcriptional activities.
In the mammary gland, the steroid receptor coactivator (SRC-
1) is coexpressed with ER in stromal cells but not in epithelial
cells [20]. This di¡erence may explain why the response of the
stroma to E2 di¡ers from that of the epithelium. Whether or
not di¡erences in interaction of ER with coactivators can
account for alterations in signaling in normal and disease
states is not known but overexpression of the ER coactivators
AIB1/SRC-3, AIB3/ASC-2/RAP250 and TRAP220/PBP have
been found in breast and ovarian cancer [21].
2. Transcriptional activities of ERK and ERL
Many but not all of the transcriptional activities of ERs are
initiated when the receptor binds to speci¢c DNA sequences
in the promoter region of the target genes. The classical con-
sensus ERE is directly bound by ERK and ERL and at this
site ERL is a weaker transactivator [22^26]. However, there
are important DNA binding sites for ER other than ERE
where ERL has di¡erent, sometimes even opposite, e¡ects
from those of ERK, e.g. at AP-1 and Sp-1 sites. Several
well-known gene promoters are regulated by AP-1 sites and
in opposite directions by ERK and ERL [27^30]. On the AP-1
site of the collagenase promoter, E2 elicits transcriptional ac-
tivation with ERK, but represses it with ERL [6]. Although the
AP-1 site has been used as a model, showing that there are
major transcriptional di¡erences between ERK and ERL, the
ER^AP-1 regulation is promoter-speci¢c rather than repre-
senting a general mechanism. For example, ERK and ERL
have similar e¡ects on the tumor necrosis factor K promoter
even though expression is regulated through an AP-1 site [31].
3. Regulation of expression of ER
A part of the promoter of both the human and mouse ERL
has been analyzed [32,33]. A 2.1-kb sequence of the 5P-£ank-
ing region of the human ERL gene shows that there are reg-
ulatory regions including Alu ERE, Oct-1, AP-1 and SP-1
sites. The Alu ERE sequence is thought to be responsible
for receptor autoregulation. E2 induces 30^40-fold increased
ERL expression in the T47D human breast cancer cell line. A
600-bp-long mouse ERL 5P-£anking region revealed the pres-
ence of a TATA-like motif and other putative transcription
factor binding sites such as GATA-1/2, AML-1/2/3, Nkx-2,
CdxA, SRY, E-box, and half-sites of EREs [33]. Of these
cis elements, GATA-1/2, AML-1/2/3, Nkx-2, CdxA, and
SRY are also found in the distal promoter of the ERK
gene. The similarities and di¡erences in the ERK and ERL
promoters predict that expression of the two ERs may be
coordinately regulated by certain transcription factors and
may also have unique cellular and tissue distribution patterns.
ERL and ERK are regulated in a tissue- and/or cell type-
speci¢c manner and E2 itself seems to play an important role
in this regulation. E2 can have opposite e¡ects on the expres-
sion of ERL and ERK. In bone mesenchymal stem cells it
increases ERK and decreases ERL, [34] in omental adipose
tissue E2 increases ERL and decreases ERK [35]. The existence
of imperfect ERE in both human and mouse ERL promoters
suggests that this response element may be involved in the E2
regulation of ERL expression. E2 and gonadotropins are the
most potent down-regulators of ERL in several tissues. E2
treatment decreases ERL expression in the immature rat ute-
rus [36], prenatally and neonatally estrogenized male rat pitui-
tary and in gonadotropin-releasing hormone neurons [37,38].
Gonadotropins down-regulate ERL in the granulosa cells,
probably via a cAMP-mediated pathway [39^41]. However,
in the newborn anterior pituitary, in the prostate and in cul-
tured breast cancer cell line T47D, E2 treatment increases
ERL expression [42^44]
4. What knockout mice have taught us about ER action
Several mouse models for the study of estrogen function are
available today. These include the knockout of aromatase
(Ar3/3), ERK (ERK3/3), ERL (ERL3/3), as well as the
knockout of both ERK and ERL (ERK3/3ERL3/3). Since
aromatase (CYP19) is the enzyme which converts C19 steroids
to estrogens, its inactivation means that these mice are com-
pletely free of E2 and all of its metabolites. Complete charac-
terization of the abnormalities in all these four E2-related
gene knockout models is still under extensive investigation
but the phenotypes of these mice have provided us with an
outline of the roles of E2 and its receptors. It is clear that,
from the di¡erences between the three single knockout mouse
models, both ERK and ERL have distinct non-redundant
physiological roles [45,46] ; in addition, the relatively milder
phenotype of Ar3/3 mice [47,48] suggests the presence in the
body of estrogenic molecules other than and in addition to
E2.
5. The uterus
As one of the major classical estrogen target tissues, the
uterus of all the three single knockout models demonstrates
the essential role of E2 signaling for the normal functions of
the uterus. This organ is considered an ERK-predominant
tissue, in which ERK is expressed in all cell types [49]. How-
ever, it is not free of ERL. Very soon after its discovery,
attempts were made to detect ERL RNA in rodent uterus
with RNase protection assays and Northern blotting. These
methods were not sensitive enough, ERL was not detected and
it was concluded that ERL is not important for the uterus
[50]. The importance of ERL in the uterus has been evaluated
in both rodents and primates [51]. In the uterus, the majority
of cells are stromal cells. With a more sensitive method for
mRNA detection, reverse transcriptase-polymerase chain re-
action, we now know that there is a fraction of the uterine
stromal cells which harbor high levels of ERL [36].
The expression of ERL in the rodent uterus has been fur-
ther evaluated with two more suitable methods, in situ hybrid-
ization and immunohistochemical staining, both of which re-
veal the cell-speci¢c expression of ERL [51,52]. These studies
showed that most of the cell types in the rat uterus (luminal
epithelial cells, glandular epithelial cells, stromal cells, smooth
muscle cells and vessel endothelial cells), harbor ERL mRNA.
But it is the subepithelial stromal cells which contain high
levels of ERL. We, and others, have shown that in the mature
uterus, ERL is expressed in the periluminal stromal cells which
are destined to undergo decidualization once implantation
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occurs. Although decidualization in ERL3/3 mice has not yet
been studied, some available data indicate that it is ERL
rather than ERK which mediates this crucial process during
implantation [54^56].
Both E2 and ERK are proliferative factors in the uterus.
This was con¢rmed in both Ar3/3 and ERK3/3 mice whose
uteri are hypoplastic. Loss of ERK results in E2-unresponsive-
ness of some known E2 target genes, e.g. lactoferrin [53].
However, ERK and E2 do not appear to be necessary for
the prepubertal development of the uterus. In both Ar3/3
and ERK3/3, there is a smaller but morphologically normal
uterus, with luminal epithelium, glandular epithelium, endo-
metrium and myometrium. The ERL3/3 mouse uterus is hy-
persensitive to the proliferative actions of E2. It appears that
ERL has a modulatory role on ERK in the uterus [36]. In
addition, the observation that the uterus in ERK3/3 mice
is bigger than it is in ERK3/3ERL3/3 mice may indicate
that in the absence of ERK, ERL can stimulate the growth
of the uterus.
The knockout mice revealed that the progesterone receptor
(PR), a long used marker for the transcriptional e¡ects of E2,
is not an exclusively ERK-regulated gene. Clearly, regulation
of PR in the uterus is not as simple as was thought. Both
PRA and PRB are detectable by Western blot analysis in
the uterus of ERK3/3 mice but in reduced amounts com-
pared to wild-type (wt) mice. The PR in the ERK3/3 uterus
is fully functional, because progesterone induces its target
genes, calcitonin and amphiregulin, and stimulates full decidu-
alization of the uterus [54]. In response to E2, PR is down-
regulated in the luminal epithelium and up-regulated in the
glandular epithelium and stroma. The down-regulation of PR
by E2 in the luminal epithelium is complex and involves par-
ticipation of both ERK and ERL.
6. The ovary
It was not until 1997, when Hurst and Leslie transfected
ERE chloramphenicol acetyltransferase plasmid into granulo-
sa cells, that it became clear that there were functional ERs in
these cells [57]. These studies were done before the existence of
ERL was widely recognized. With ERL antibodies, the ER
status in the ovary has been widely investigated. Generally,
ERL is localized in the granulosa cells of growing follicles and
may also be expressed in some stromal cells [58,59]. ERK is
mainly expressed in the theca cells and some stromal cells
[58,60]. Granulosa cells may not be free of ERK but this
remains a debated issue [61].
The ovary is a tissue in which the individual roles of E2,
ERK and ERL are clearly delineated. E2 is mainly produced
in the granulosa cells of the ovary during female reproductive
age, and ERK is mainly expressed in the interstitial stromal
cells and theca cells while ERL is predominantly expressed in
the granulosa cells (Fig. 3B). It seems that neither aromatase,
ERK nor ERL is necessary for embryonic development of the
ovary, because the females of all three mouse models have
morphologically normal ovaries before puberty. Although
the ovaries of both ERK3/3 and Ar3/3 mice display an
age-dependent hemorrhagic cystic phenotype, these abnormal-
ities appear not to be directly related to the loss of ERK or E2
from the ovary itself. The ovarian abnormalities of Ar3/3
and ERK3/3 mice appear to be due to the increased serum
luteinizing hormone levels. When ERK3/3 mice receive go-
nadotropins, they do ovulate and form corpora lutea capable
of producing progesterone [62]. These data indicate that ERK
is not directly involved in the process of ovulation.
Hemorrhagic cysts appear in Ar3/3 mouse ovaries at
around 10 weeks of age when animals are kept on a soy-
Fig. 3. Comparison of ovaries from wt and ERL3/3 mice. Morphological appearance of wt (A) and ERL3/3 mouse (C) ovaries showing
abundant corpora lutea in wt but not in ERL3/3 ovaries. In B the localization of ERL in granulosa cells of wt mice is illustrated. Fixed sec-
tions of ovaries from wt (B) and ERL3/3 mice (D) have been stained for ERL with a C-terminal antibody.
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free diet [47], while ERK3/3 mice show the phenotype just at
the commencement of sexual maturity around 5 weeks of age
[66]. The delayed appearance of the ovarian phenotype in
Ar3/3 mice indicates that Ar3/3 mice may not be estro-
gen-free, though they are E2-free. Despite this, ovaries of
ERK3/3ERL3/3 and Ar3/3 mice have a unique phenotype
not presented in either ERK3/3 or ERL3/3 mice. This is the
appearance of Sertoli-like cells in the ovary [64,65]. In addi-
tion, in ERK3/3ERL3/3 ovaries there are no preovulatory
follicles or corpora lutea and the granulosa cells are strati¢ed.
All of this suggests that the presence of both ERK and ERL is
crucial for the normal function of the female gonad.
The ovaries of ERL3/3 mice are distinctly di¡erent from
those of Ar3/3 and ERK3/3 mice. Instead of forming hem-
orrhagic cysts, the ERL3/3 mouse ovary shows accelerated
follicular atresia and severely reduced ovulation [46,63]. Cor-
pora lutea are rare (Fig. 3A). Gonadotropin treatment does
not appear to increase either the number of oocytes or the
number of corpora lutea in ERL3/3 mice. These data suggest
that there is a direct involvement of granulosa cell ERL in the
process of ovulation [66]. Though some reports describe the
female ERL3/3 mice as subfertile, in our lab we have not
been able to generate more than a few pregnant ERL3/3
mice over three years of trying. There is quite a large variabil-
ity in the degree of subfertility of ERL3/3 mice. The reason
for this is not clear. In our colony, ERL3/3 females very
rarely become pregnant. Of those who do deliver pups, the
litter size is small (one to three pups), and most of the dams
eat their pups shortly after birth. We have come to the con-
clusion that the atretic follicles of the ERL3/3 mouse ovary
is only one factor contributing to ERL3/3 mouse subfertility.
There appear to be additional uterine and behavioral abnor-
malities in female ERL3/3 mice.
7. The mammary gland
ERL is found in both the epithelial cells (ductal and lobu-
lar) and stromal cells and even during embryogenesis in the
rodent mammary gland [67]. ERK is expressed in both the
ductal epithelium and stroma, not in the lobular epithelium.
In the epithelium, 60^70% of cells express ERL at all stages of
breast development. Cells co-expressing ERK and ERL are
rare during pregnancy, a proliferative phase, but they repre-
sent up to 60% of the epithelial cells during lactation, a post-
proliferative phase [13]. One of the most fascinating aspects of
ERs in the breast is their dual role in both proliferation and
di¡erentiation. It still remains unresolved whether the prolif-
erative e¡ects of E2 on the epithelium are exclusively medi-
ated by growth factors released from the stroma under E2
stimulation. During pregnancy, the proliferating cell nuclear
antigen is not expressed in ERK-positive cells and is observed
in 3^7% of ERL-containing cells. More than 90% of ERL-
expressing cells do not proliferate [13].
Severe retardation of mammary gland development has
been found in both Ar3/3 and ERK3/3 mice. In adult fe-
males of both genotypes, the mammary glands are rudimen-
tary. Though ERK is expressed in the epithelium of normal
mammary gland, and E2 can induce epithelial growth in the
presence of progesterone, the mammary gland phenotype in
ERK3/3 mice appears not to be due to the local absence of
ERK in the gland itself. When wt pituitary glands were trans-
planted into ERK3/3 mice, their mammary glands responded
to E2 and progesterone in terms of ductal branching and
lobular growth [68]. These responses may be due either to
the presence of ERL in the gland, to the e¡ects of the aberrant
ERK splice variant observed in ERK3/3 mice [69], or to non-
receptor-mediated action of E2.
The mammary glands of prepubertal ERL3/3 mice are
morphologically indistinguishable from those of wt litter-
mates. It appears that, although ERL is expressed in the
mouse mammary gland, it is not necessary for ductal growth
of the gland. However, ultrastructural analysis [70] revealed a
role for ERL in organization and adhesion of epithelial cells.
This was particularly evident in lactating glands, where lack of
ERL resulted in larger alveoli and a reduced amount of secre-
tory epithelium, increased interepithelial distance and reduced
extracellular matrix and lamina basalis. Levels of the adhesion
molecules E-cadherin, connexin 32, occludin and integrin K2
were reduced and no zona occludens was detectable.
8. The ventral prostate
In the ventral prostate ERL is abundant and ERK absent or
very low. Before the discovery of ERL, ERK had been local-
ized exclusively in the prostatic stroma of several species and
thus the e¡ects of E2 in the prostate epithelium were thought
to be indirectly mediated by stromal ER [71,72]. In situ hy-
bridization and immunohistochemical staining with di¡erent
ERL antibodies have revealed that ERL is localized in the
prostatic epithelium in most species and that direct e¡ects of
E2 on the epithelial cells are possible [14,73^75]. Currently our
views on the action of E2 in the prostate epithelial cells are
being revised to accommodate these new ¢ndings.
Hyperplastic prostates have been described in Ar3/3 [76]
and ERL3/3 mice [14] but not in ERK3/3 mice. Because no
hormonal alteration has been found in the ERL3/3 mouse
serum, epithelial hyperplasia in the ventral prostate appears to
be directly due to loss of ERL in the prostate. However, the
hyperplastic phenotype of Ar3/3 prostate could, in addition
to the loss of ERL, also be due to the increased androgen and
prolactin levels in the Ar3/3 mouse serum.
9. The CNS
ERK-containing neurons are located in the medial preoptic
area, periventricular nucleus, arcuate nucleus, ventromedial
nucleus, and amygdala, all areas involved in gonadally regu-
lated functions [77,78]. ERL is expressed in the cerebral cor-
tex, hippocampus, as well as paraventricular nucleus and the
supraoptic nucleus areas where ERK is not found [79,80]. The
two receptors are colocalized in the preoptic area, bed nucleus
of the stria terminalis and throughout the lower brainstem.
The distribution pattern suggests di¡erent functions for the
two receptors in the brain. It could be anticipated that brain
phenotypes of the mice in which either of these receptors has
been inactivated should be di¡erent. No morphological
changes have been reported in mice lacking ERK but there
are striking morphological abnormalities in the brains of
ERL3/3 mice [81,82].
In the brains of ERL3/3 mice, layers 2 and 3 of the so-
matosensory cortex are very reduced and there is a severe
neuronal de¢cit throughout the cortex. In addition, particu-
larly in the substantia nigra, neuronal cell bodies are small
and there are large vacuoles surrounding the cell nuclei. In the
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limbic system there is a remarkable proliferation of astroglia.
Further investigation revealed that there is a problem of neu-
ronal migration in the absence of ERL [82]. Although prolif-
eration appears to be normal, there are fewer neurons in the
cortex and abnormal migration patterns are evident. Even
though abnormalities in the brains of Ar3/3 mice have
been reported [83], unlike ERL3/3 mice, there is no evidence
for proliferation of astroglia in Ar3/3 mice (Fig. 4). The
di¡erences between the brains of ERL3/3 and Ar3/3 mice
suggest that Ar3/3 mice are not completely estrogen-free and
hint at an alternative estrogen or an alternative route for
activation of ERs in the body.
10. Alternative estrogen receptor ligands in the body
Two of the major metabolites of the potent androgen 5K-
dihydrotestosterone (DHT) are also potent hormones. These
two steroids, 5K-androstane-3K,17L-diol (3KAdiol) and 5K-an-
drostane-3L,17L-diol (3LAdiol; Fig. 2), although they are epi-
mers, have very di¡erent biological actions. 3KAdiol is andro-
genic, and 3LAdiol is estrogenic. 3KAdiol functions as a weak
androgen by itself or, through the action of 3K-hydroxysteroid
dehydrogenase (3KHSD), is reconverted to the potent andro-
gen DHT [84]. It has no estrogenic e¡ects. 3LAdiol is formed
from DHT through the action of 3LHSD. It does not itself
have androgenic activity [85] but it can be reconverted to
DHT since 3LHSD activity is reversible. The estrogenic activ-
ity of 3LAdiol has been well documented. It can displace E2
from ERK [86,87]. Compared to E2 its a⁄nity is lower by 10-
fold for ERL and 30-fold for ERK [88].
In some in vivo experiments, it has been di⁄cult to show
estrogenic activity of 3LAdiol. Uterine growth and vaginal
strati¢cation were observed when high doses of 3LAdiol (14
mg/kg body weight) were used to treat hypophysectomized
rats [89]. With a lower dose (1 mg/kg body weight) there
were no uterotrophic e¡ects but 3LAdiol delayed the onset
of ¢rst ovulation [90]. Furthermore, in vivo, 3LAdiol has no
e¡ect on serum gonadotropin levels while 3KAdiol e¡ectively
suppresses gonadotropin serum concentration. These in vivo
data have led some endocrinologists to believe that 3LAdiol
has no important physiological functions itself, and is only as
a metabolite of androgen.
The physiological levels of 3LAdiol make its role intriguing.
In the prepubertal female rat, the serum level of 3LAdiol is
quite high, around 100 ng/ml. After the ¢rst ovulation, it
decreases to 10 pg/ml [91]. The origin of 3LAdiol in the im-
mature female is the ovary. Not much attention has been paid
to the steroids secreted from the immature ovary because it
does not synthesize estradiol. However, the immature ovary is
not a silent tissue. Even though their physiological signi¢cance
is not understood, substantial quantities of 3KAdiol and 3LA-
diol are synthesized in the immature ovary [91]. In the imma-
ture testis, as in the immature ovary, a large amount of 3LA-
diol is produced, with a peak between postnatal day 10 and
day 25. Thereafter, plasma levels decline [92]. At maturity, the
plasma concentration of 3LAdiol in the male rat is around 200
pg/ml [93]. This is about 20 times higher than the level of
estradiol in the adult male rat [94]. Considering that its a⁄n-
ity for ERL is 10-fold lower than that of E2, 3LAdiol could
well serve as a physiological ligand for ERL.
Tissue levels of 3LAdiol are regulated by the enzyme 3LA-
diol hydroxylase, a member of the cytochrome P450 super-
family, identi¢ed as CYP 7B1. 3LAdiol is hydroxylated at the
6K or 7K positions and these triols are the ¢nal, inactivated
urinary metabolites of DHT. 3LAdiol hydroxylase activity is
high in the prostate, brain, and pituitary but it is not detect-
able in the liver [95,96]. It seems that the estrogenicity of
3LAdiol in a cell is determined by the presence or absence
of CYP 7B1 [97]. In cells where CYP 7B1 is highly expressed
3LAdiol will be inactivated and will not be estrogenic. This
might explain why low doses of 3LAdiol do not regulate go-
nadotropin secretion from the pituitary.
11. ERL splice variants
There is one further confounding factor in the estrogen
action equation. This factor is the splice variants of ERL.
Several splice variants of ERL have been described (Fig.
1C; see [98] for review). One which is of particular interest
because of its expression in human cancers is ERLcx [6]. In
this splice variant, an alternative exon 8 is utilized. The last 61
C-terminal amino acids (exon 8) are replaced by 26 unique
amino acid residues. Due to the exchange of the last exon,
ERLcx lacks amino acid residues important for ligand binding
Fig. 4. Astroglia in the medial amygdala nucleus of male wt (left), Ar3/3 (middle) and ERL3/3 mice (right). Astroglia are detected by the
marker protein GFAP. As shown, there are very few astroglia in the medial amygdala of normal and Ar3/3 mouse, but many are seen in the
ERL3/3 mice.
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and those that constitute the core of the AF2 domain. It
therefore does not bind E2 and has no capacity to activate
transcription of an E2-sensitive reporter gene. ERLcx shows
preferential heterodimerization with ERK rather than with
ERL, inhibiting ERK DNA binding. Functionally, the hetero-
dimerization of ERLcx with ERK has a dominant negative
e¡ect on ligand-dependent ERK reporter gene transactivation.
Emerging studies on the ERL isoforms in prostate and breast
cancer indicate that ERLcx is expressed as a protein [99] and
its presence in cancers can in£uence prognosis and recurrence.
12. Concluding remarks
The known or suspected functions of many genes have been
con¢rmed and new unsuspected functions of many genes have
been revealed with knockout mice. While clear roles of ERK
and ERL are being intensively studied in experimental models,
aberrant ER expression in several human diseases is also
being examined and studies suggest important roles of both
receptors in malignancies of the breast, prostate, lung, colon
and ovary and in non-malignant diseases such as polycystic
ovarian syndrome, endometriosis, cardiovascular disease, obe-
sity, osteoporosis and degenerative diseases of the CNS. Be-
cause of the existence of ERL isoforms which can have quite
di¡erent biological functions, information about E2 action in
human diseases must be considered incomplete if ERL and its
isoforms as well as ERK are not speci¢ed.
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